Oppenheimer Initiates ProQR Therapeutics(PRQR.US) With Buy Rating, Announces Target Price $15
Oppenheimer Initiates ProQR Therapeutics at Outperform With $15 Price Target
Express News | ProQR Therapeutics NV : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $15
Is There An Opportunity With ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 37% Undervaluation?
ProQR Therapeutics N.V. (NASDAQ:PRQR) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
Chardan Capital Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Maintains Target Price $4
thanks you